References
- Early Breast Cancer Trialists Collaborative Group (EBCTCG). Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998;352: 930–42.
- National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): Breast cancer version1.2014. 01-01-2014.
- Sukel M, van de Poll-Franse L, Nieuwenhuijzen G, Vreugdenhil G, Herings R, Coebergh J, et al. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990–2006 in the southeastern Netherlands. Eur J Cancer 2008;44:1846–54.
- Dutch Cancer Society and Comprehensive Cancer Centers, The Netherlands. Cijfers over borstkanker. 2013. 3-6-2014.
- Stiggelbout AM, de Haes JCJM, van de Velde CJH. Adjuvant chemotherapy in node negative breast cancer: Patterns of use and oncologists’ preferences. Ann Oncol 2000;11:631–3.
- Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA. Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor positive breast cancer. J Clin Oncol 2004;22:3309–15.
- Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006;99:215–20.
- Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556–62.
- Engelhardt E, Pieterse A, an Duijn-Bakker N, Kroep J, de Haes J, Smets E, et al. Breast cancer specialists’ views on and use of risk prediction models in clinical practice: A mixed methods approach. Acta Oncol Epub 2014 Oct 2013.
- Wouters H, Maatman GA, Van Dijk L, Bouvy ML, Vree R, Van Geffen ECG, et al. Trade-off preferences regarding adjuvant endocrine therapy among women with estrogen receptor-positive breast cancer. Ann Oncol 2013;24:2324–9.
- Schmidt M, Victor A, Bratzel D, Boehm D, Cotarelo C, Lebrecht A, et al. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer: Comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial. Ann Oncol 2009;20:258–64.
- Engelhardt EG, Garvelink MM, de Haes JH, van der Hoeven JJ, Smets EM, Pieterse AH, et al. Predicting and communicating the risk of recurrence and death in women with early-stage breast cancer: A systematic review of risk prediction models. J Clin Oncol 2014;32:238–50.